The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Q1 2025 Management View Mike Exton, Chief Executive Officer, highlighted a pivotal exclusive license agreement with Novo Nordisk for LX9851, stating "this agreement grants Novo an exclusive worldwide ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

Novo Holdings, a global life sciences investor, today announced its investment in SCHOTT Poonawalla, India's leading provider ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Scientists herald 150 new jabs and pills to tackle obesity going through the research pipeline - but issue urgent warning to ...

The world's first commercial-scale e-methanol plant began operations in Denmark on Tuesday, with shipping giant Maersk set to ...

The National Institute for Health and Care Excellence (Nice) previously stopped its appraisal of semaglutide (Wegovy) for use ...

ParticipACTION will kick off its search for Canada's Most Active Community with the ParticipACTION Community Challenge ...

Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless ...